Stifel raised the firm’s price target on Astera Labs (ALAB) to $200 from $185 and keeps a Buy rating on the shares following a “strong” Q3 beat and “meaningful guidance raise.” Astera’s PCIe portfolio “already is in prime position” to capture meaningfully accelerating revenue in 2026 and 2027, even as the company expands its portfolio to address next-gen protocols, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALAB:
- Astera Labs price target raised to $215 from $180 at JPMorgan
- Astera Labs, Inc.: Strong Growth and Promising Prospects Drive Buy Rating
- Astera Labs Reports Strong Q3 2025 Financial Performance
- Hold Rating on Sean O’Loughlin: Balancing Strong Performance with Growth Investment and Competitive Uncertainties
- Astera Labs price target raised to $225 from $200 at Roth Capital